Defence Therapeutics Inc.
DTCFF
$0.6447
-$0.3517-35.30%
OTC PK
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 1.37% | -35.65% | |||
| Depreciation & Amortization | -2.31% | -63.38% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.11% | -58.71% | |||
| Operating Income | -19.11% | 58.71% | |||
| Income Before Tax | -29.24% | 54.85% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -29.24% | 54.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -29.24% | 54.85% | |||
| EBIT | -19.11% | 58.71% | |||
| EBITDA | -19.62% | 58.16% | |||
| EPS Basic | -26.53% | 54.84% | |||
| Normalized Basic EPS | -27.87% | 54.81% | |||
| EPS Diluted | -26.53% | 54.84% | |||
| Normalized Diluted EPS | -27.87% | 54.81% | |||
| Average Basic Shares Outstanding | 1.45% | 0.07% | |||
| Average Diluted Shares Outstanding | 1.45% | 0.07% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||